Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580

被引:22
|
作者
Sumida, T [1 ]
Otani, H [1 ]
Kyoi, S [1 ]
Okada, T [1 ]
Fujiwara, H [1 ]
Nakao, Y [1 ]
Kido, M [1 ]
Imamura, H [1 ]
机构
[1] Kansai Med Univ, Dept Thorac & Cardiovasc Surg, Cardiovasc Res Ctr, Moriguchi, Osaka 5708507, Japan
关键词
necrosis; contractility;
D O I
10.1152/ajpheart.01183.2004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
p38 MAP kinase activation is known to be deleterious not only to mitochondria but also to contractile function. Therefore, p38 MAP kinase inhibition therapy represents a promising approach in preventing reperfusion injury in the heart. However, reversal of p38 MAP kinase-mediated contractile dysfunction may disrupt the fragile sarcolemma of ischemic-reperfused myocytes. We, therefore, hypothesized that the beneficial effect of p38 MAP kinase inhibition during reperfusion can be enhanced when contractility is simultaneously blocked. Isolated and perfused rat hearts were paced at 330 rpm and subjected to 20 min of ischemia followed by reperfusion. p38 MAP kinase was activated after ischemia and early during reperfusion (<30 min). Treatment with the p38 MAP kinase inhibitor SB-203580 (10 mu M) for 30 min during reperfusion, but not the c-Jun NH2-terminal kinase inhibitor SP-600125 (10 mu M), improved contractility but increased creatine kinase release and infarct size. Cotreatment with SB-203580 and the contractile blocker 2,3-butanedione monoxime (BDM, 20 mM) or the ultra-short-acting beta-blocker esmorol (0.15 mM) for the first 30 min during reperfusion significantly reduced creatine kinase release and infarct size. In vitro mitochondrial ATP generation and myocardial ATP content were significantly increased in the heart cotreated with SB-203580 and BDM during reperfusion. Dystrophin was translocated from the sarcolemma during ischemia and reperfusion. SB-203580 increased accumulation of Evans blue dye in myocytes depleted of sarcolemmal dystrophin during reperfusion, whereas cotreatment with BDM facilitated restoration of sarcolemmal dystrophin and mitigated sarcolemmal damage after withdrawal of BDM. These results suggest that treatment with SB-203580 during reperfusion aggravates myocyte necrosis but concomitant blockade of contractile force unmasks cardioprotective effects of SB-203580.
引用
收藏
页码:H2726 / H2734
页数:9
相关论文
共 50 条
  • [31] P38 mitogen-activated protein kinase inhibitor SB203580 has a bi-directional effect on iNOS expression and NO production
    Lahti, A
    Kankaanranta, H
    Moilanen, E
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 454 (2-3) : 115 - 123
  • [32] A p38 MAP kinase inhibitor SB203580 inhibits CD28-dependent T cell proliferation and IL-2 production.
    Ward, SG
    Parry, RV
    Matthews, J
    ONeill, L
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) : S304 - S304
  • [33] p38 mitogen activated protein kinase inhibitor SB203580 attenuate the mechanical allodynia in neuropathic pain model.
    Mizokoshi, A
    Tsuda, M
    Shigemoto-Mogami, Y
    Koizumi, S
    Inoue, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2003, 91 : 187P - 187P
  • [34] Cytosolic phospholipase A2 activation by the p38 kinase inhibitor SB203580 in rabbit aortic smooth muscle cells
    Fatima, S
    Khandekar, Z
    Parmentier, JH
    Malik, KU
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 298 (01): : 331 - 338
  • [35] Inhibition of p38 MAP kinases, by SB 203580 abolishes the infarct size reduction by ischaemic preconditioning in pigs
    Belosjorow, S
    Schulz, R
    Gres, P
    Behrends, M
    Heusch, G
    EUROPEAN HEART JOURNAL, 2001, 22 : 688 - 688
  • [36] Synthesis of RWJ 68354: A potent inhibitor of the MAP kinase p38
    Henry, JR
    Dodd, JH
    TETRAHEDRON LETTERS, 1998, 39 (48) : 8763 - 8764
  • [37] SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts
    Nakano, A
    Cohen, MV
    Critz, S
    Downey, JM
    BASIC RESEARCH IN CARDIOLOGY, 2000, 95 (06) : 466 - 471
  • [38] SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts
    Atsushi Nakano
    Michael V. Cohen
    Stuart Critz
    James M. Downey
    Basic Research in Cardiology, 2000, 95 : 466 - 471
  • [39] Myocardial ischemia/reperfusion causes VDAC phosphorylation which is reduced by cardioprotection with a p38 MAP kinase inhibitor
    Schwertz, Hansjorg
    Carter, Justin M.
    Abdudureheman, Mulati
    Russ, Martin
    Buerke, Ute
    Schlitt, Axel
    Mueller-Werdan, Ursula
    Prondzinsky, Roland
    Werdan, Karl
    Buerke, Michael
    PROTEOMICS, 2007, 7 (24) : 4579 - 4588
  • [40] Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38
    Lal, AS
    Clifton, AD
    Rouse, J
    Segal, AW
    Cohen, P
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 259 (02) : 465 - 470